Our heritage

Biocodex is a family-owned company founded more than 70 years ago to market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from a French pioneer to an international player in the microbiota realm.

Biocodex’s history

The history of Biocodex started in the 1920’s with the discovery of the yeast Saccharomyces boulardii in Indochina by Henri Boulard, a French biologist. At that time, cholera epidemics were common in Asia. Henri Boulard took a strong interest in tropical diseases.

The agronomist observed that in order to treat the infectious diarrhea caused by cholera, Indochinese people consumed a drink based on lychees and mangosteens. Henri Boulard decided to study in detail the composition of the lychee and mangosteen skins. He then identified a specific yeast from the Saccharomyces family, the unique Saccharomyces boulardii CNCM I-745® strain Biocodex produces today.

Henri Boulard at the roots of probiotics

This docufiction film takes us back to the early 20th century, when agronomist Henri Boulard discovered a passion for plants and yeast, the living microorganisms capable of provoking fermentation. The film traces Boulard’s journey in Indochina, leading to his discovery of the world’s first probiotic yeast strain for human medicine.

Biocodex’s unique strain

In 1953, Biocodex acquired the rights to Henri Boulard’s yeast strain and fermentation process, and in 1961, the company registered lyophilized Saccharomyces boulardii CNCM I-745® as a drug. This unique strain was deposited at the Institut Pasteur(Paris) in 1989.

  • More than 100 scientific studies have proven the efficacy of our unique strain
  • Trusted by doctors 460 MILLION people have been treated with Saccharomyces boulardii CNCM I-745 since its commercialization 
Saccharomyces boulardii CNCM I-745

In addition to gastroenterology, Biocodex has also developed scientific expertise in other therapeutic areas such as pain, neurology and general medicine. With the acquisition of Laboratoires Iprad in early 2020, Biocodex now also focuses on women’s health.